FDA Approves Weekly Diabetes Drug.

reports the Food and Drug Administration approved Novo Nordisk’s weekly-injection diabetes drug Ozempic (semaglutide), which is in a class of drugs called glucagon-like peptide-1 (GLP-1) analogs. The article reports that Novo hopes Ozempic “will take market share from” Eli Lilly’s Trulicity, which is also a GLP-1 analog. https://www.reuters.com/article/us-novo-nordisk-diabetes-fda/fda-approves-novo-nordisk-diabetes-drug-ozempic-idUSKBN1DZ2O9